Effects of MDR1 gene C3435T polymorphism on pharmacokinetics of cyclosporine A in myasthenia gravis patients

Abstract

Abstract: AIM: To determine the effects of MDR1 C3435T on the pharmacokinetics of cyclosporine A in myasthenia gravis patients.METHODS: The genotype on MDR1 C3435T in 96 myasthenia gravis patients was detected using real-time PCR method and 73 patients of them were studied further to determine the relationship of MDR1 C3435T polymorphism and trough blood concentrations of cyclosporine A.RESULTS: There were no difference between normal people and myasthenia gravis patients inMDR1 C3435T distribution.The average concentrations in patient of MDR1 3435CC was higher than that in patients of MDR1 3435CT and 3435TT.CONCLUSION: The pharmacogenomics is important to rationalize the medication of cyclosporine A.

Key words: MDR1, myasthenia gravis, cyclosporine A, real-time PCR, pharmacogenomics

CLC Number:

R966

ZHANG Ya-tong, YANG Li-ping, SHAO Hong, Li Ke-xin, SUN Chun-hua, SHI Lu-wen. Effects of MDR1 gene C3435T polymorphism on pharmacokinetics of cyclosporine A in myasthenia gravis patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(2): 133-136.

References

1 Morita N, Yasumori T, Nakayama K.Human MDR1 polymorphism:G2677T/A and C3435T have no effect on MDR1 transport activities[J].Biochem Pharm, 2003;65:1843-52
2 Sakaeda T, Nakamura T, Okumura K.Pharmacogenetics of drug transporters and its impact on the pharmacotherapy[J]. Curr TopMed Chem, 2004;4:1385-98
3 Song PF, Shen L, Meibohm B, Gaber AO, Honaker MR, Kotb M, et al.Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: mdr1 single nucleotide polymorphism genotyping assay [J]. AAPS PharmSci, 2002;4:29
4 von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW.No influence of the mdr1 C3435T polymorphism or a cyp3a4 promoter polymorphism (cyp3a4-v allele) on doseadjusted cyclosporin a trough concentrations or rejection incidence in stable renal transplant recipients[J].Clin Chem, 2001;47:1048-52
5 岑宇翔, 陆志诚, 汪华侨.汉族人MDR1C3435T 基因的多态性[J].解剖学研究, 2004;26:50-3
6 梁剑宁, 李耀明, 张惠文.MDR1C3435T 基因多态性的检测[J].现代临床医学生物工程学杂志, 2003;9:72-5
7 Ameyaw MM, Regateiro F, Li T, Liu X, TariqM, Mobarek A, et al.MDR1 pharmacogenetics:frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity[J].Pharmacogenetics, 2001;11:217-21
8 Chowbaya B, Cumaraswamyb S, Cheungc YB, Zhou Q, Lee EJ.Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients[J].Pharmacogenetics, 2003;13:89-95
9 Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al.Identification of functionally variant MDR1 alleles among European Americans and African Americans[J]. Clin Pharmacol Ther, 2001;70:189-99
10 Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, et al.MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects[J].Pharm Res, 2001;18:1400-4
11 Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P, et al.Effect of grapefruit juice on digoxin pharmacokinetics in humans[J].Clin Pharmacol Ther, 2001;70:311-6
12 Min DI, Ellingrod VL.C3435T mutation in exon 26 of the human MDR1 gene and cy closporine harmacokinetics in healthy subjects[J].Ther Drug Monit, 2002;24:400-4
13 Balram C, Sharma A, Sivathasan C, Lee EJ.Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population:phenotypic-genotypic correlates[J].Br J Clin Pharmacol, 2003;56:78-83

[1]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[2]	SUN Yuanyuan, DENG Kunhong, WANG Siyi, KUANG Yun, ZOU Chan, GUO Chengxian, HE Qingnan, LIU Helin, YANG Guoping. Design and implementation of electronic identity application for gene-directed personalized medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 274-280.
[3]	XING Kai, GONG Jinyu, LUO Jianquan. Advances on pharmacogenomics of diuretics-related adverse reactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 204-212.
[4]	. Research Progress of Pharmacogenomics of Dabigatran Etexilate and Rivaroxaban [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1200-1207.
[5]	YANG Shucai，ZHANG Li，LIU Liping，DENG Weijie，ZHOU Jie，LIU Hui，ZHANG Baohu，JIN Tao. Effect of hypoxia-inducible factor 2α on chemoresistance of hepatocellular carcinoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 630-636.
[6]	XIE Shangchen, LI Wei, LIAO Ping, HE Yijing, MCLEOD Howard L.. Research progress of general anesthesia in the pharmacogenetics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 217-222.
[7]	WANG Chanyue, WANG Ye, ZHANG Peipei, CHEN Mingyue, YANG Hao, ZHU Manli, LI Linlin. Relationship of Fusobacterium nucleatum levels in gut microbiota with type 2 diabetes mellitus in Uygurs of Xinjiang [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1321-1325.
[8]	ZHAO De-heng, XIAO Hui-lai. FDA's recommentdations on pharmacogenomics studies in early-phase clinical studies [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 208-212.
[9]	ZHANG Yue-li, MING Ying-zi, ZHOU Hong-hao, ZHANG Wei. Tacrolimus pathways:pharmacokinetics,pharmacodynamics and pharmacogenomics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 1042-1049.
[10]	DAI Ying, ZHANG Jing, LIN Mei-qing, SONG Hong-tao. Research current situation and progress on pharmacogenomics and personalized medicine of cyclosporine A [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 931-936.
[11]	OUYANG Cang-hong, XIE Juan. Study on the relationship between the MDR1 and CYP3A genetic polymorphisms and serum digoxin concentration in 111 patients with chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 291-296.
[12]	LIN Mei-qin, ZHANG Jing, YU Liang-ping, SONG Hong-tao. Advances of individualized administration model of warfarin based on pharmacogenomics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(11): 1299-1305.
[13]	CAO Ying-ya, LU Wei-hua, JIANG Xiao-gan, LU Mei-jing, WU Jing-yi, QIN Xue-mei, YAO Wei-dong. Difference in time-course of relaxant effect of rocuronium in acetylcholine receptors antibody seropositive and seronegative patients with myasthenia gravis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(10): 1153-1157.
[14]	TAO Ran, HUANG Hong-guang, GAO Li-chen. Advances in pharmacogenomics research of adverse effects of hypertension therapy drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(10): 1183-1188.
[15]	HUANG Zheng-yu, LIU Fang-qun, GAO Li-chen, WANG Di, HE Yi-jing, CHENG Xiao-ping. Advances in pharmacogenomics of cyclophosphamide in the breast cancer therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(10): 1196-1200.